Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Nuron Licenses Alzheimer’s Vaccine

By Drug Discovery Trends Editor | April 10, 2012

Nuron Biotech Inc. announced it has licensed from Vitruvian BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer’s disease (AD). Nuron has an exclusive, worldwide license for the vaccine and is responsible for development and commercialization. Unlike a traditional vaccine for AD, the DNA vaccine does not contain amyloid beta itself but instead contains a piece of the gene coding for the amyloid beta protein. Once in the body, the vaccine stimulates an immune response in which antibodies that bind to and significantly reduce amyloid beta are produced. Financial terms were not disclosed.

“This unique, promising vaccine candidate brings more opportunity to our pipeline and is one of the most promising new advances to improve the lives of Alzheimer’s patients worldwide,” said Shankar Musunuri, PhD, MBA, Chief Executive Officer and Founder of Nuron Biotech. “Alzheimer’s is a devastating neurodegenerative disease for which there is only a limited set of therapy options, so this novel approach to treatment is truly exciting.”

“We are very pleased to be working with Nuron in developing this important vaccine,” commented Arthur Bollon, Ph.D., Chief Executive Officer and Founder of Vitruvian BioMedical. “Research has shown that this adjuvant-free DNA vaccine is far superior to a peptide-based vaccine as it significantly reduces the levels of Aβ42, by about 50% in preclinical models, and importantly, it does not generate an inflammatory immune response in the brain.” The vaccine candidate was created at the University of Texas Southwestern Medical Center.

In the United States alone, Alzheimer’s disease currently affects 5.4 million people and their families. It is the most common form of dementia and the fifth leading cause of death for individuals 65 years and older. The Alzheimer’s Association estimates that the disease results in $200 billion dollars of healthcare costs in the United States each year.

Date: April 9, 2012
Source: Nuron Biotech Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE